TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fidelity of intervention delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diminishing of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerable Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Feasible Dose (MFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HIV RNA < 200 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TB coinfection status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of VO2max from 1st week to 12th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of maximal exercise work from 1st week to 12th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of 6-minute walk test from 1st week to 12th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum interleukin-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: soluble interleukin-6 receptor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success or failure of eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-free Survival (EFS) - Number of Participants With an Event
Endpoint domain: Mortality/survival
Primary endpoint: EFS - Time to Event
Endpoint domain: Mortality/survival
Primary endpoint: Food Insecurity Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CSF pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified PASI (Psoriasis area and severity index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline to Day 18 in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline to Day 18 in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline to Day 18 in pulse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline to Day 18 in body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory biomarkers on FDG-PET-MRI imaging after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in fasting plasma triglycerides concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C1 inhibitor serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: C4 antigen serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radiographic Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Allergen Solo EAR PD20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Psychiatric comorbidities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Needle Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABI Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence or absence of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: %Methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Catheter Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of eosinophils in the oesophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of mepolizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving <40 Copies/mL HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sound of lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sphygmomanometer blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease free progression
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity (Treatment related side effects)
Endpoint domain: Adverse events/effects
Primary endpoint: Nutrient composition of human milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUSCAN pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Death, Myocardial Infarction, Recurrent Ischemia Requiring Urgent Revascularization, and Thrombotic Bail-out
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability of the study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of antibiotic associated diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Identified as a Responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AR transcriptional activity based on expression of AR regulated genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: memory retention of the Canadian CT Head Rule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of fit testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhalation to Exhalation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of specific cross-reactive L. loa antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: relief of discomfort symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants experiencing Adverse Events (AE) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Urine biomarkers correlation with IC/PBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell-free Mitochondrial DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Necrosis Factor-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychiatric problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infrapopliteal arterial patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduced Symptom Burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Clinical Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of gastrointestinal diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of deep venous thrombosis or pulmonary emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of ODSH in pediatric patients
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin Secretion-Sensitivity Index (IS-SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neurodevelopmental Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decayed tooth surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rebleeding Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Pathological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: middle ear status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the cystoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Restoration of menstrual cycle regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum KHK4827 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of HCPs providing the correct response
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of Parents/Carers providing the correct response
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of men who could avoid repeat biopsy using mp-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of men who could avoid repeat biopsy using Prostate HistoScanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Staphylococcus Aureus Bacteremia and/or Deep Sternal Wound Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Vaccine-related Serious Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With pT2 Prostate Cancer Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic accuracy of the prediction model for adenomyosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life (t½λz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Insecurity (During)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS Anxiety (During)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS Stress Perception (During)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive COVID-19 IgG formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sealants failure
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in 4-meter walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Crohn's Disease Activity Index (CDAI) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Medication Errors
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Severity of Adverse Drug Events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Medication Errors
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin-mediated Glucose Disposal Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Blood Perfusion (Blood Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Blood Perfusion (Mean Flow Velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Blood Perfusion (Relative Blood Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of days spent at home within the first 30 days after surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of days in the hospital after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of days admitted to an extended care facility after discharge from the hospital
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Major complications after bariatric surgery
Endpoint domain: Adverse events/effects
Primary endpoint: 28-day transplantation-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in the FACIT-D questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Convergence Insufficiency Symptom Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: implant's primary stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory gating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events due to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With All Cause Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Laboratory Abnormalities in Specific Liver Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changed dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With at Least One Skin Rash (Folliculitis)
Endpoint domain: Adverse events/effects
Primary endpoint: Back Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-for-age z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length-for-age z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight-for-length z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Head-circumference-for-age z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body-mass-index (BMI)-for-age z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With ACR 20 Response at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With ACR 20 Response at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of PrEP adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of BPPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gametocytemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Asexual parasitemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum TNF-α level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum IL-1β level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Urticaria Activity Score 7 (UAS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cardiac death or non-fatal myocardial infarction or ischemia-driven target vessel revascularisation
Endpoint domain: Mortality/survival
Primary endpoint: Change in physiological measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Strength Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in edema quantity at 30th postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in seroma quantity at 30th postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vitamin A in TRL fraction of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Infusion Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Delayed Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Formation of New Anti-HLA Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of occult pathology (malignant and benign)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity and specificity of ductal lavage to duct endoscopy in detecting atypia or malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in the periodontal pocket depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the gingival margin (GM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the width of the keratinized tissue (KT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borderline Symptoms List (BSL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Clinical Impression of BPD (GCI-BPD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Borderline Evaluation of Severity Over Time (BEST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stop benzodiazepine abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects experiencing dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: source memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in severity level of ASD symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Bacterial Contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decline in triglycerides level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in GAGS index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Care Seeking Behavior around complications and well baby check-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Perceived Improved Ease of Self-administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ventilation Defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Advance Care Planning Documentation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: NET formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Plasma HIV-1 RNA Level <50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: New DWI Lesion(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hamilton Depression Rating Scale, HAM-D
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck Depression Inventory(BDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pittsburgh Sleep Quality Inventory
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: WHOQOL-Taiwan
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Change from baseline trough FEV1 percent predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-III sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommendation of health care provider
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Quality of Health Care Provider Relationship and Communication Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Adherence to Clinical Standards of Care Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Incidence of acute aortic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of major bleedings defined as overt bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with symptomatic recurrent venous thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with positive response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of geriatric patients with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CD8 T-cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC0-t of tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects experiencing Dose Limiting Toxicities with ALLO-501
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients experiencing Dose Limiting Toxicity with ALLO-647
Endpoint domain: Adverse events/effects